Alaunos Therapeutics Inc
TCRT2.782USD
+0.042+1.53%
Market hours （ET）Quotes delayed by 15 min
4.45MMarket Cap
LossP/E TTM
More Details of Alaunos Therapeutics Inc Company
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.
Company Info
Ticker SymbolTCRT
Company nameAlaunos Therapeutics Inc
IPO dateAug 20, 2004
CEOMr. Holger Weis, CPA
Number of employees1
Security typeOrdinary Share
Fiscal year-endAug 20
Address2617 Bissonnet St
CityHOUSTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code77005
Phone13463554099
Websitehttps://alaunos.com/
Ticker SymbolTCRT
IPO dateAug 20, 2004
CEOMr. Holger Weis, CPA
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.21K
--
Mr. Robert W. Postma
Mr. Robert W. Postma
Independent Director
Independent Director
--
--
Mr. Jaime W. Vieser
Mr. Jaime W. Vieser
Independent Director
Independent Director
--
--
Mr. Ferdinand Groenewald
Mr. Ferdinand Groenewald
Vice President - Finance
Vice President - Finance
--
--
Mr. Michael Jerman
Mr. Michael Jerman
Director
Director
--
--
Ms. Melinda Lackey, J.D.
Ms. Melinda Lackey, J.D.
Legal and Administrative Officer, Corporate Secretary
Legal and Administrative Officer, Corporate Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.21K
--
Mr. Robert W. Postma
Mr. Robert W. Postma
Independent Director
Independent Director
--
--
Mr. Jaime W. Vieser
Mr. Jaime W. Vieser
Independent Director
Independent Director
--
--
Mr. Ferdinand Groenewald
Mr. Ferdinand Groenewald
Vice President - Finance
Vice President - Finance
--
--
Mr. Michael Jerman
Mr. Michael Jerman
Director
Director
--
--
Ms. Melinda Lackey, J.D.
Ms. Melinda Lackey, J.D.
Legal and Administrative Officer, Corporate Secretary
Legal and Administrative Officer, Corporate Secretary
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Jul 4
Updated: Fri, Jul 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
PMGC Capital LLC
4.22%
Watermill Asset Management
1.69%
Vieser (Jaime W.)
1.69%
Postma (Robert W.)
1.68%
BlackRock Institutional Trust Company, N.A.
1.08%
Other
89.65%
Shareholders
Shareholders
Proportion
PMGC Capital LLC
4.22%
Watermill Asset Management
1.69%
Vieser (Jaime W.)
1.69%
Postma (Robert W.)
1.68%
BlackRock Institutional Trust Company, N.A.
1.08%
Other
89.65%
Shareholder Types
Shareholders
Proportion
Investment Advisor
4.26%
Corporation
4.22%
Individual Investor
3.65%
Investment Advisor/Hedge Fund
0.80%
Hedge Fund
0.08%
Bank and Trust
0.07%
Research Firm
0.06%
Other
86.86%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
153
252.48K
13.08%
-146.72K
2025Q1
169
296.91K
17.46%
-90.28K
2024Q4
182
298.15K
18.62%
-116.62K
2024Q3
208
422.39K
26.38%
-38.04K
2024Q2
224
471.36K
29.44%
+11.94K
2024Q1
281
305.54K
19.08%
-201.69K
2023Q4
302
346.05K
21.58%
-260.76K
2023Q3
324
525.07K
33.28%
-179.72K
2023Q2
339
599.70K
37.93%
-192.22K
2023Q1
357
606.92K
38.76%
-233.79K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
PMGC Capital LLC
83.50K
4.22%
+83.50K
--
May 12, 2025
Watermill Asset Management
33.33K
1.69%
+33.33K
--
Jun 24, 2025
Vieser (Jaime W.)
29.93K
1.83%
+17.46K
+140.07%
Apr 30, 2025
Postma (Robert W.)
29.10K
1.47%
-33.34K
-53.40%
Jun 24, 2025
BlackRock Institutional Trust Company, N.A.
21.35K
1.08%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
20.97K
1.06%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
15.61K
0.79%
+394.00
+2.59%
Mar 31, 2025
UBS Financial Services, Inc.
6.63K
0.34%
--
--
Mar 31, 2025
Hogue (Dale Curtis Jr.)
4.44K
0.22%
+442.00
+11.05%
Apr 30, 2025
Tower Research Capital LLC
1.68K
0.08%
+527.00
+45.87%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Biotechnology ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
iShares Biotechnology ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
Jan 29, 2024
Merger
15<1
Jan 29, 2024
Merger
15<1
Date
Type
Ratio
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
Jul 16, 2024
Merger
10<1
Jan 29, 2024
Merger
15<1
Jan 29, 2024
Merger
15<1
Jan 29, 2024
Merger
15<1
Jan 29, 2024
Merger
15<1
